Inovio Pharmaceuticals specializes in DNA-based immunotherapies for HPV-related conditions, cancer, and infectious diseases. The company's flagship drug, INO-3107, shows promise for treating recurrent ...
Inovio’s upside hinges on INO-3107 for HPV-6/11 RRP with FDA PDUFA Oct 2026, regulatory risk, tight cash, and cheap EV. Check out why INO stock is a buy.
Shares of Inovio Pharmaceuticals INO jumped 20.6% on Wednesday after the FDA agreed to the company’s rolling submission timeline for the biologics license application (BLA) seeking approval for ...
Shares of Inovio Pharmaceuticals pulled back by 5.3% during Wednesday’s session. The decline may be attributed to profit-taking, as investors assess renewed focus on respiratory illnesses. See the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results